Year : 2025 | Volume : 12 | Issue : 01 | Page : 28-46

Komal G. Sangu,

Shweta R. Gupta,

Pranita D. Shigwan,

Kajal S. Prajapati,

Anchal P. Verma,

Assistant Professor, Department of Pharmaceutical Chemistry, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Maharashtra, India
Assistant Professor, Department of Pharmaceutical Chemistry, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Maharashtra, India
Assistant Professor, Department of Pharmaceutical Chemistry, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Maharashtra, India
Assistant Professor, Department of Pharmaceutical Chemistry, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Maharashtra, India
Assistant Professor, Department of Pharmaceutical Chemistry, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Maharashtra, India

Abstract

The year 2024 has been pivotal for the pharmaceutical industry, with the U.S. Food and Drug Administration (FDA) granting approval to a diverse array of new drugs. These approvals highlight significant strides in therapeutic innovation, targeting a spectrum of diseases from rare genetic disorders to prevalent chronic conditions. This article provides a detailed examination of the FDA-approved drugs of 2024, focusing on their therapeutic indications, mechanisms of action, and the clinical trial evidence, side effects and storage conditions. Notable approvals include groundbreaking treatments in cardiovascular health, infectious diseases, neurology, and oncology, each offering novel therapeutic options and potential improvements in patient outcomes. About 41 drugs have been approved by USFDA till June 2024. This comprehensive review aims to inform healthcare professionals and researchers of the latest advancements, fostering a deeper understanding of emerging trends in drug development and their implications for future medical practice.

Keywords: FDA Approval, Pharmaceutical Innovations, USFDA approved drugs 2024, Clinical Trials, Drug Development.

[This article belongs to Research & Reviews: A Journal of Drug Formulation, Development and Production ]

How to cite this article:
Komal G. Sangu, Shweta R. Gupta, Pranita D. Shigwan, Kajal S. Prajapati, Anchal P. Verma. FDA Drug Approvals 2024: A Comprehensive Review. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2025; 12(01):28-46.

How to cite this URL:
Komal G. Sangu, Shweta R. Gupta, Pranita D. Shigwan, Kajal S. Prajapati, Anchal P. Verma. FDA Drug Approvals 2024: A Comprehensive Review. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2025; 12(01):28-46. Available from: https://journals.stmjournals.com/rrjodfdp/article=2025/view=196002

References

1. U.S. Food and Drug Administration. Novel Drug Approvals for 2024 https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
2. New Drug Approvals https://www.drugs.com/newdrugs.html
3. Keam. S.J, ‘Berdazimer Topical Gel, 10.3%: First Approval’ Drugs 2024, 84(3), pp.363-368.
4. Olatunji. G, Kokori. E, Kwape. J.M, Fawehinmi. P, Stanley. A.C, Oluwatobiloba. A.M, Abraham. I.C, Shimelis. K.M, Olafimihan. A, Ezeano. C. and Ologbe. D, ‘Berdazimer: A novel nitric oxide therapy in treating molluscum contagiosum’, J. Med .Surg. Public Health. 2024, 2, p.100061.
5. Centers for Disease Control and Prevention (CDC). Molluscum Contagiosum Treatment.
6. Fitch, J., 2024. FDA approves prescription berdazimer gel, 10.3% to treat molluscum 6. J. Fitch, ‘FDA Approves Prescription Berdazimer Gel, 10.3% to Treat Molluscum Contagiosum: Berdazimer Gel Demonstrates Positive, Topline Data in the Phase 3 B-SIMPLE4 Trial in Patients 6 Months or Older with Raised Molluscum Contagiosum Lesions’, Contemp. Pediatr. 2024, 40, 14–15.
7. J.C. Browning, C. Enloe, M. Cartwright, A. Hebert, A.S. Paller, D. Hebert, E.K. Kowalewski, T. Maeda-Chubachi, ‘Efficacy and Safety of Topical Nitric Oxide− Releasing Berdazimer Gel in Patients with Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial’, JAMA Dermatol. 2022, 158, 871–878.
8. B. Alex, ‘FDA Approves Takeda’s EOHILIA (Budesonide Oral Suspension), the First and Only Oral Treatment in the US for Eosinophilic Esophagitis (EoE)’.
9. J. Lee, R. Dierkhising, T.T. Wu, J. Alexander, C. Weiler, ‘Eosinophilic Gastrointestinal Disorders (EGID) with Peripheral Eosinophilia: A Retrospective Review at Mayo Clinic’, Dig. Dis. Sci. 2011, 56, 3254–3261.
10. S.D. Khangura, C. Spry, ‘Budesonide Extended Release for Ulcerative Colitis: CADTH Health Technology Review’, 2023.
11. Mayo Clinic, ‘Eosinophilic Esophagitis Treatment Information’, https://www.mayoclinic.org.
12. A. Karal, H. Celik, ‘Drugs and Natural Products Used in COPD’, Int. J. Innov. Res. Rev. 2022, 6, 51–58.
13. J. Krause, F. Brokmann, C. Rosenbaum, W. Weitschies, ‘The Challenges of Drug Delivery to the Esophagus and How to Overcome Them’, Expert Opin. Drug Deliv. 2022, 19, 119–131.
14. Biktarvy HIV Medication Update, ‘Biktarvy HIV Medication Update’, Nurse Pract. 2024, 49.
15. J. Tay, V. Barbier, F.M. Helwani, G.R. Price, J.P. Levesque, I.G. Winkler, ‘Prostacyclin is an Endosteal Bone Marrow Niche Component and its Clinical Analog Iloprost Protects Hematopoietic Stem Cell Potential During Stress’, Stem Cells 2021, 39, 1532–1545.
16. A. McClean, ‘Evaluating Biosimilars Uptake and Policy in Canada’, Ph.D. Thesis, University of British Columbia, 2022.
17. S.M. Konda, J.A. Woodward, ‘A Comprehensive Review of Use of Neurotoxins for Periocular Rejuvenation’, Int. Ophthalmol. Clin. 2024, 64, 51–59.
18. C. Rasetti-Escargueil, S. Palea, ‘Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications’, Toxins 2024, 16, 261.
19. F. Braccini, I. Catoni, F. Belfkira, J. Lagier, E. Roze, J. Paris, V. Bronsard, H. Cartier, M. David, O. Galatoire, ‘SAMCEP Society Consensus on the Treatment of Upper Facial Lines with Botulinum Neurotoxin Type A: A Tailored Approach’, J. Cosmet. Dermatol. 2023, 22, 2692–2704.
20. D.S. Aschenbrenner, ‘New Biosimilar Drugs Approved for Osteoporosis’, Am. J. Nurs. 2024, 124, 16.
21. M.V. Deligiorgi, D.T. Trafalis, ‘The Safety Profile of Denosumab in Oncology Beyond the Safety of Denosumab as an Anti-Osteoporotic Agent: Still More to Learn’, Expert Opin. Drug Saf. 2021, 20, 191–213.
22. C. Rowan, R. Ungaro, S. Mehandru, J.F. Colombel, ‘An Overview of Ozanimod as a Therapeutic Option for Adults with Moderate-to-Severe Active Ulcerative Colitis’, Expert Opin. Pharmacother. 2022, 23, 893–904.
23. J.A. Cohen, G. Comi, D.L. Arnold, A. Bar-Or, K.W. Selmaj, L. Steinman, E.K. Havrdová, B.A. Cree, X. Montalbán, H.P. Hartung, V. Huang, ‘Efficacy and Safety of Ozanimod in Multiple Sclerosis: Dose-Blinded Extension of a Randomized Phase II Study’, Mult. Scler. J. 2019, 25, 1255–1262.
24. W.J. Sandborn, B.G. Feagan, D.C. Wolf, G. D’Haens, S. Vermeire, S.B. Hanauer, S. Ghosh, H. Smith, M. Cravets, P.A. Frohna, R. Aranda, ‘Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis’, N. Engl. J. Med. 2016, 374, 1754–1762.
25. L. Rasche, F. Paul, ‘Ozanimod for the Treatment of Relapsing Remitting Multiple Sclerosis’, Expert Opin. Pharmacother. 2018, 19, 2073–2086.
26. T. Avni, L. Leibovici, I. Cohen, A. Atamna, D. Guz, M. Paul, A. Gafter-Gvili, D. Yahav, ‘Tocilizumab in the Treatment of COVID-19—A Meta-Analysis’, QJM 2021, 114, 577–586.
27. J.A. Singh, S. Beg, M.A. Lopez-Olivo, ‘Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review’, J. Rheumatol. 2011, 38, 10–20.
28. S.Y. Liu, Y.L. Wu, ‘Tislelizumab: An Investigational Anti-PD-1 Antibody for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)’, Expert Opin. Investig. Drugs 2020, 29, 1355–1364.
29. S. Qin, R.S. Finn, M. Kudo, T. Meyer, A. Vogel, M. Ducreux, T.M. Macarulla, G. Tomasello, F. Boisserie, J. Hou, X. Li, ‘RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma’, Future Oncol. 2019, 15, 1811–1822.
30. M. Kokkorakis, C. Boutari, M.A. Hill, V. Kotsis, R. Loomba, A.J. Sanyal, C.S. Mantzoros, ‘Resmetirom, the First Approved Drug for the Management of Metabolic Dysfunction-Associated Steatohepatitis: Trials, Opportunities, and Challenges’, Metabolism 2024, 154.
31. S.A. Harrison, M. Bashir, S.E. Moussa, K. McCarty, J. Pablo Frias, R. Taub, N. Alkhouri, ‘Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients with NASH’, Hepatol. Commun. 2021, 5, 573–588.
32. N. Alkhouri, ‘Thyromimetics as Emerging Therapeutic Agents for Nonalcoholic Steatohepatitis: Rationale for the Development of Resmetirom (MGL-3196)’, Expert Opin. Investig. Drugs 2020, 29, 99–101.
33. G. Karim, M.B. Bansal, ‘Resmetirom: An Orally Administered, Small-Molecule, Liver-Directed, β-Selective THR Agonist for the Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis’, touchREV Endocrinol. 2023, 19, 60.
34. A. Philippidis, ‘Orchard Therapeutics Gains First US Approval for a Metachromatic Leukodystrophy Gene Therapy’, Hum. Gene Ther. 2024, 35, 215–218.
35. A.A. Qureshi, A.S. Aswad, S. BKM&D, A.H. Saeed, H. Tabassum, M.F. Tahir, ‘Breaking Ground: Lenmeldy’s Approval and the Future of MLD Treatment’.
36. F. Barada, M. pharmD, ‘Recent and Anticipated Novel Drug Approvals (Q2 2024 through Q1 2025)’, Am. J. Health-Syst. Pharm. 2024, Ram, C.V.S., A New Class of Drugs Approved in the United States for Hypertension: Endothelin Antagonists. The American Journal of Medicine.
37. J. Xu, X. Jiang, S. Xu, ‘Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: mechanism of action and therapeutic potential’, Drug Discov. Today 2023, 103788.
38. S. Thomas, ‘Aprocitentan (TRYVIO)’, Amrita J. Med. 2024, 20, 83–85.
39. M.H. Rim, B.L. Karas, F. Barada, C. Dean, A.M. Levitsky, ‘Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025)’, Am. J. Health-Syst. Pharm. 2024, zxae148.
40. A. Raucci, C. Castiello, A. Mai, C. Zwergel, S. Valente, ‘Heterocycles-Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years’, ChemMedChem 2024, e202400194.
41. P. Konieczny, ‘Systemic Treatment of Body-Wide Duchenne Muscular Dystrophy Symptoms’, Clinical Pharmacology & Therapeutics.
42. R. Team, ‘Macitentan and Tadalafil (Opsynvi)’, Can. J. Health Technol. 2022, 2, 2.
43. J.L. Ford, A. Sabet, J. Natarajan, H. Stieltjes, D.L. Chao, N. Goyal, D. Csonka, ‘Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed-dose combination tablets versus the use of single-component tablets in healthy subjects’, Pharmacol. Res. Perspect. 2024, 12, e1202.
44. A.A.A. Allergy, E.E.E.E.E. Endocrinology, G.G.G.G.G. Gastroenterology, H.H. Hepatology, P.P.P.P. Pain, P.P.P.P.P. Pulmonology, R.R.R.R.R. Rheumatology, R.R.R.R. Rheumatology, S.S. Sleep, Q. Corner, ‘Estimating the Risk of Operative Mortality in Patients with Cardiogenic Shock Undergoing CABG Surgery: Insights from the Society of Thoracic Surgeons National Cardiac Database’, Age 50, 55-59.
45. C. Kang, ‘Sotatercept: First Approval’, Drugs 2024, 1–6.
46. A. Markham, ‘Vadadustat: first approval’, Drugs 2020, 80, 1365–1371.
47. V.H. Haase, ‘Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease’, Kidney Int. Suppl. 2021, 11, 8–25.
48. A. Papapetropoulos, S. Topouzis, S.P. Alexander, M. Cortese-Krott, D.A. Kendall, K.A. Martemyanov, C. Mauro, N. Nagercoil, R.A. Panettieri, H.H. Patel, R. Schulz, ‘Novel drugs approved by the EMA, the FDA, and the MHRA in 2023’, 2024.
49. C.M. DeBoer, D.K. Rasmussen, J.A. Franco, V.B. Mahajan, ‘Emerging Oral Pharmaceuticals for Dry Age-Related Macular Degeneration: Mechanism of Action, Current Clinical Status, and Future Directions’, Ophthalmic Surg. Lasers Imaging Retina 2024, 1–7.
50. V.P. Peixoto, C. Prudêncio, M. Vieira, ‘Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials’, Curr. Med. Res. Opin. 2024, 1–20.
51. A. Davis, ‘The benefits and pitfalls of participating in a corporate inversion: a case study of two companies on two different paths (Doctoral dissertation)’, 2015.
52. R. Consta, U. Rykindo, ‘Clinical Policy: Risperidone Long-Acting Injection (Perseris, Risperdal).
53. U. Kumar, B. Mohanty, ‘Atypical antipsychotic paliperidone prevents behavioral deficits in mice prenatally challenged with bacterial endotoxin lipopolysaccharide’, Eur. J. Pharmacol. 2015, 747, 181–189.
54. J. Singh, ‘Ceftobiprole medocaril (Zevtera)–FDA approved antibiotic for three infections including methicillin-resistant Staphylococcus aureus’, J. Mol. Chem. 2024, 4, 692–692.
55. A.N. Deitchman, D. de Jong, A.M. Barbour, H. Derendorf, ‘Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections’, Expert Rev. Anti Infect. Ther. 2016, 14, 997–1006.
56. Y.Y. Syed, ‘Ceftobiprole medocaril: a guide to its use in hospital-or community-acquired pneumonia in the EU’, Drugs & Ther. Perspect. 2015, 31, 150–156.
57. M.D. Scala, T. Werner, M. Nicklasson, N. Onetto, M.R. Scott, M.S.D. Skolsky, M.D. Veitch, M. Engelhardt, G. Hauck, M.A. Kaul, L. Kellenberger, ‘Swissmedic approves Basilea’s antibiotic Zevtera®(ceftobiprole medocaril) for the treatment of pneumonia’, Oncology 2014, 2013.
58. S. Mofid, W.R. Bolislis, T.C. Kühler, ‘Real-world data in the postapproval setting as applied by the EMA and the US FDA’, Clin. Ther. 2022, 44, 306–322.
59. M. Ferraresi, D.L. Panzieri, S. Leoni, M.D. Cappellini, A. Kattamis, I. Motta, ‘Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease’, Eur. J. Pediatr. 2023, 182, 2509–2519.
60. O. Cingoz, ‘Ustekinumab’, MAbs 2009, 1, 216–221.
61. J.J. Hong, E.K. Hadeler, M.L. Mosca, N.D. Brownstone, T. Bhutani, W.J. Liao, ‘TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: Therapeutic utility in the era of IL-17 and IL-23 inhibitors’, J. Psoriasis Psoriatic Arthritis. 2022, 7, 79–92.
62. J. Wu, J. Smogorzewski, ‘Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases’, Dermatol. Ther. 2021, 34, e14883.
63. D.J. Cada, T.L. Levien, D.E. Baker, ‘Ustekinumab’, Hospital Pharmacy 2010, 45, 320–331.
64. A. Brinker, C. Cheng, V. Chan, ‘Association of noninfectious pneumonia with ustekinumab use’, JAMA dermatol. 2019, 155, 221–224.
65. J. Xu, X. Jiang, S. Xu, ‘Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: mechanism of action and therapeutic potential’, Drug Discov. Today 2023, 103788.
66. S. Thomas, ‘Aprocitentan (TRYVIO)’, Amrita J. Med. 2024, 20, 83-85.
67. M.H. Rim, B.L. Karas, F. Barada, C. Dean, A.M. Levitsky, ‘Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025)’, Am. J. Health-Syst. Pharm. 2024, zzae148.
68. A. Raucci, C. Castiello, A. Mai, C. Zwergel, S. Valente, ‘Heterocycles‐Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years’, ChemMedChem 2024, e202400194.
69. P. Konieczny, ‘Systemic Treatment of Body‐Wide Duchenne Muscular Dystrophy Symptoms’, Clin. Pharmacol. Ther.
70. R. Team, ‘Macitentan and Tadalafil (Opsynvi)’, Can. J. Health Technol. 2022, 2, 2.
71. J.L. Ford, A. Sabet, J. Natarajan, H. Stieltjes, D.L. Chao, N. Goyal, D. Csonka, ‘Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed‐dose combination tablets versus the use of single‐component tablets in healthy subjects’, Pharmacol. Res. Perspect. 2024, 12, e1202.
72. Brinker, A., Cheng, C., Chan, V., ‘Association of noninfectious pneumonia with ustekinumab use’, JAMA Dermatol. 2019, 155(2), pp.221-224.
73. Kakehi, Y., Iida, M., Naemura, T., Shirai, Y., Matsushita, M., Ohguro, T., ‘Lumisight table: Interactive view-dependent display-table surrounded by multiple users’, In ACM SIGGRAPH 2004 Emerging Technol. 2004, p.18.
74. Doe-Simkins, M., Walley, A.Y., Epstein, A., Moyer, P., ‘Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose’, Am. J. Public Health 2009, 99(5), pp.788-795.
75. D’Arrigo, T., ‘MedCheck: High-Dose Naloxone, Tavapadon, Tirzepatide, and Lumateperone’, 2024.
76. Zaks, A., Jones, T., Fink, M., Freedman, A.M., ‘Naloxone treatment of opiate dependence: A progress report’,JAMA, 1971, 215(13), pp.2108-2110.
77. Kurz, M., Belani, K.G., Sessler, D.I., Kurz, A., Larson, M.D., Schroeder, M., Blanchard, D., ‘Naloxone, meperidine, and shivering’, Anesthesiology 1993, 79(6), pp.1193-1201.
78. Chamie, K., Chang, S.S., Rosser, C.J., Kramolowski, E., Gonzalgo, M.L., Sexton, W.J., Spilman, P., Sender, L., Reddy, S., Soon-Shiong, P., ‘N-803 Plus BCG Treatment for BCG-Naïve or-Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review’, Future Oncol. 2024, pp.1-11.
79. Holmes, B., ‘Interleukin-Based Treatments Find Footing in Ongoing Research’, 2022.
80. Fu, Y., Tang, R., Zhao, X., ‘Engineering cytokines for cancer immunotherapy: a systematic review’, Front. Immunol. 2023, 14, p.1218082.
81. Dhillon, S., ‘Tovorafenib: First Approval’, Drugs, 2024, pp.1-9.
82. Bakker, A., Barrett, C., Roy, U.B., Hopper, J., Hurlbert, M., Kerkorian, C., Kieran, M., Ludwinski, D., Weinstein, A., ‘Advancing Pediatric Cancer Research and Drug Development Through Multistakeholder Collaboration’, 2024.
83. Inman, S., ‘Future Is Bright for Targeted Immunotherapy in Brain Cancer’.
84. Rim, M.H., Karas, B.L., Barada, F., Dean, C., Levitsky, A.M., ‘Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025)’, Am. J. Health-Syst. Pharm. 2024, p.zxae148.
85. Harris, E., ‘New Drug for UTIs Gets the Greenlight’, JAMA 2024, 331(23), pp.1982-1983.
86. Parsons, R.L., Hossack, G.A., Paddock, G.M., ‘Pharmacokinetics of pivmecillinam’, Br. J. Clin. Pharmacol. 1977, 4(3), pp.267-273.
87. Baselga, J., ‘Clinical trials of Herceptin® (trastuzumab)’, Eur. J. Cancer 2001, 37, pp.18-24.
88. Harries, M., Smith, I., ‘The development and clinical use of trastuzumab (Herceptin)’, Endocr. Relat. Cancer 2002, 9(2), pp.75-85.
89. Hudis, C.A., ‘Trastuzumab—mechanism of action and use in clinical practice’, N. Engl. J. Med. 2007, 357(1), pp.39-51.
90. Hortobagyi, G.N., ‘Trastuzumab in the treatment of breast cancer’, N. Engl. J. Med. 2005, 353(16), pp.1734-1736.
91. Rogawski, M.A., Heller, A.H., ‘Diazepam buccal film for the treatment of acute seizures’, Epilepsy Behav. 2019, 101, p.106537.
92. Kotloski, R.J., Gidal, B.E., ‘Rescue treatments for seizure clusters’, Neurol. Clin. 2022, 40(4), pp.927-937.
93. Asnis-Alibozek, A., Detyniecki, K., ‘The unmet need for rapid epileptic seizure termination (REST)’, Epilepsy Behav. Rep. 2021, 15, p.100409.
94. Detyniecki, K., Penovich, P., ‘New Options for Rescue Treatment in Individuals With Epilepsy Seizure Clusters’, Prim. Care Companion CNS Disord. 2021, 23(6), p.38551.
95. Treon, S.P., Buske, C., Thomas, S.K., Castillo, J.J., Branagan, A.R., Dimopoulos, M.A., Gavriatopoulou, M., Cadavid, D., Garzon, F.T., Tang, W., Seyffert, S., ‘Preliminary clinical response data from a phase 1b study of mavorixafor in combination with ibrutinib in patients with Waldenström’s macroglobulinemia with MYD88 and CXCR4 mutations’, Blood 2021, 138, p.1362.
96. Miao, M., De Clercq, E., Li, G., ‘Clinical significance of chemokine receptor antagonists’, Expert Opin. Drug Metab. Toxicol. 2020, 16(1), pp.11-30.
97. Rim, M.H., Karas, B.L., Barada, F., Dean, C., Levitsky, A.M., ‘Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025)’, Am. J. Health-Syst. Pharm. 2024, p.zxae148.
98. Motlak, M., Mathews, M., Al-Odat, O.S., Pandey, M.K., ‘Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?’, Cytokine 2024, 179, p.156629.
99. Castaman, G., Miesbach, W., ‘Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives’, Semin. Thromb. Hemost. 2024, Thieme Medical Publishers, Inc.
100. Klamroth, R., Cuker, A., Alzahrani, H., Astermark, J., Frenzel, L., Katsarou, O., Kavakli, K., Matino, D., Shapiro, A., Wang, J.D., Fuiman, J., ‘Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Results from the Phase 3 BENEGENE-2 Gene Therapy Trial’, Hämostaseologie, 2024, 44(S 01), pp.T-12.
101. Pittman, D.D., Carrieri, C., Soares, H., McKay, J., Tan, C.Y., Liang, J.Z., Rakhe, S., Marshall, J.C., Murphy, J.E., Gaitonde, P. and Rupon, J., ‘Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec’, Thromb. Haemost. 2024.
102. Azurity Pharmaceuticals, Inc., ‘Common Side Effects of Myhibbin (33)’, Azurity Pharmaceuticals, Inc., 2024.
103. Azurity Pharmaceuticals, Inc., ‘Safety Profile of Myhibbin (33)’, Azurity Pharmaceuticals, Inc., 2024.
104. Conroy, R., ‘Tarlatamab Earns FDA Priority Review in Advanced Small Cell Lung Cancer’, Cancer Network, 2023.
105. Ahn, M.J., Cho, B.C., Felip, E., Korantzis, I., Ohashi, K., Majem, M., Juan-Vidal, O., Handzhiev, S., Izumi, H., Lee, J.S. and Dziadziuszko, R., ‘Tarlatamab for patients with previously treated small-cell lung cancer’, N. Engl. J. Med. 2023, 389(22), pp.2063-2075.
106. Chen, P.W., Minocha, M., Kong, S.M., Anderson, E.S., Parkes, A., Martinez, P., Houk, B.E. and Lin, C.W., ‘Exposure-efficacy and exposure-safety relationships of tarlatamab to inform dose selection and benefit-risk assessment in patients with advanced small cell lung cancer (SCLC)’, Cancer Res. 2024, 84(6_Supplement), p.7164.
107. Gaya, A. and Tse, V., ‘A preclinical and clinical review of aflibercept for the management of cancer’, Cancer Treat. Rev. 2012, 38(5), pp.484-493.
108. Ciombor, K.K., Berlin, J. and Chan, E., ‘Aflibercept’, Clin. Cancer Res., 2013, 19(8), pp.1920-1925.
109. Sharma, A., Loewenstein, A., Kumar, N., Parachuri, N., Bandello, F. and Kuppermann, B.D., ‘Aflibercept biosimilars – update on the development progress’, Eye 2024, 38(5), pp.824-825.
110. Bressler, N.M., Kaiser, P.K., Do, D.V., Nguyen, Q.D., Park, K.H., Woo, S.J., Sagong, M., Bradvica, M., Kim, M.Y., Kim, S. and Sadda, S.R., ‘Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review’, Surv. Ophthalmol. 2024.
111. Sensoy, E. and Citirik, M., ‘Current biosimilar anti-VEGF drugs in retinal diseases’, Eur. Eye Res. 2024, 4(2), pp.0-0.
112. Tris Pharma, Inc., ‘FDA Approval Letter’, May 26, 2024.
113. Tris Pharma, Inc., ‘Onyda XR Prescribing Information’, Tris Pharma, Inc., May 2024.
114. National Institutes of Health, ‘ADHD Treatments and Drugs’, Available at: https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml
115. American Academy of Pediatrics, ‘Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents’, Pediatrics, October 2019, 144(4).
116. FDA approval announcement for Bkemv: ‘FDA Approves Bkemv for Treatment of Specific Blood Disorders’.
117. Tris Pharma, Inc., official website for Bkemv: ‘Bkemv Information’.
118. Clinical trial information and efficacy data for Bkemv: ‘Clinical Trials for Bkemv’.
119. Safety profile and adverse reactions of Bkemv: ‘Safety Profile of Bkemv’.
120. Das, R., ‘Update on Moderna’s RSV Vaccine, mRESVIA (mRNA-1345), in Adults ≥ 60 Years of Age’, 2024.
121. Britton, A., Melgar, M. and Roper, L., ‘Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years, 60–74 years, and 75 years and older’, 2024.
122. Tregoning, J.S., ‘The tricky second album: Licensure of an mRNA vaccine for respiratory syncytial virus’, Mol. Ther. 2024.
123. Tefferi, A., Lasho, T.L., Begna, K.H., Patnaik, M.M., Zblewski, D.L., Finke, C.M., Laborde, R.R., Wassie, E., Schimek, L., Hanson, C.A. and Gangat, N., ‘A pilot study of the telomerase inhibitor imetelstat for myelofibrosis’, N. Engl. J. Med. 2015, 373(10), pp.908-919.
124. Mosoyan, G., Kraus, T., Ye, F., Eng, K., Crispino, J.D., Hoffman, R. and Iancu-Rubin, C., ‘Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis’, Leukemia 2017, 31(11), pp.2458-2467.
125. Frost, G., Liu, Y., Kron, S. and Scheidt, K., ‘Telomerase Reverse Transcriptase Degradation via a Rationally Designed Covalent Proteolysis Targeting Chimera’.
126. Westerouen Van Meeteren, M.J., Drenth, J.P. and Tjwa, E.T., ‘Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)’, Expert Opin. Investig. Drugs, 2020, 29(2), pp.117-123.
127. Ratziu, V., Harrison, S.A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S. and Drenth, J., ‘Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening’, Gastroenterology 2016, 150(5), pp.1147-1159.
128. Sookoian, S. and Pirola, C.J., ‘Elafibranor for the treatment of NAFLD: One pill, two molecular targets and multiple effects in a complex phenotype’, Ann. Hepatol. 2016, 15(4), pp.604-609.

Regular Issue Subscription Review Article

Research & Reviews: A Journal of Drug Formulation, Development and Production

ISSN: 2394-1944

Volume	12
Issue	01
Received	18/01/2025
Accepted	21/01/2025
Published	30/01/2025
Publication Time	12 Days

Total Visits: 201

PlumX Metrics

Initiatives

Legal Information

Contact Us

STM Journals
An imprint of Consortium E-learning network Pvt. Ltd.
A-118, 1st Floor, Sector-63, Noida, U.P. India, Pin-201301
(Tel) (+91) 0120- 4781 200
(Mob) (+91) 9810078958, +919667725932
[email protected]

Join Us

Submit Manuscript

Submit Topics

WEBSITE DISCLAIMER

Last updated: 2022-06-15

The information provided by STM Journals (“Company”, “we”, “our”, “us”) on https://journals.stmjournals.com/ (the “Site”) is for general informational purposes only. All information on the Site is provided in good faith, however, we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information on the Site.

UNDER NO CIRCUMSTANCE SHALL WE HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE SITE OR RELIANCE ON ANY INFORMATION PROVIDED ON THE SITE. YOUR USE OF THE SITE AND YOUR RELIANCE ON ANY INFORMATION ON THE SITE IS SOLELY AT YOUR OWN RISK.

EXTERNAL LINKS DISCLAIMER

The Site may contain (or you may be sent through the Site) links to other websites or content belonging to or originating from third parties or links to websites and features. Such external links are not investigated, monitored, or checked for accuracy, adequacy, validity, reliability, availability, or completeness by us.

WE DO NOT WARRANT, ENDORSE, GUARANTEE, OR ASSUME RESPONSIBILITY FOR THE ACCURACY OR RELIABILITY OF ANY INFORMATION OFFERED BY THIRD-PARTY WEBSITES LINKED THROUGH THE SITE OR ANY WEBSITE OR FEATURE LINKED IN ANY BANNER OR OTHER ADVERTISING. WE WILL NOT BE A PARTY TO OR IN ANY WAY BE RESPONSIBLE FOR MONITORING ANY TRANSACTION BETWEEN YOU AND THIRD-PARTY PROVIDERS OF PRODUCTS OR SERVICES.

PROFESSIONAL DISCLAIMER

The Site can not and does not contain medical advice. The information is provided for general informational and educational purposes only and is not a substitute for professional medical advice. Accordingly, before taking any actions based on such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical advice.

Content published on https://journals.stmjournals.com/ is intended to be used and must be used for informational purposes only. It is very important to do your analysis before making any decision based on your circumstances. You should take independent medical advice from a professional or independently research and verify any information that you find on our Website and wish to rely upon.

THE USE OR RELIANCE OF ANY INFORMATION CONTAINED ON THIS SITE IS SOLELY AT YOUR OWN RISK.

AFFILIATES DISCLAIMER

The Site may contain links to affiliate websites, and we may receive an affiliate commission for any purchases or actions made by you on the affiliate websites using such links.

TESTIMONIALS DISCLAIMER

The Site may contain testimonials by users of our products and/or services. These testimonials reflect the real-life experiences and opinions of such users. However, the experiences are personal to those particular users, and may not necessarily be representative of all users of our products and/or services. We do not claim, and you should not assume that all users will have the same experiences.

YOUR RESULTS MAY VARY.

The testimonials on the Site are submitted in various forms such as text, audio, and/or video, and are reviewed by us before being posted. They appear on the Site verbatim as given by the users, except for the correction of grammar or typing errors. Some testimonials may have been shortened for the sake of brevity, where the full testimonial contained extraneous information not relevant to the general public.

The views and opinions contained in the testimonials belong solely to the individual user and do not reflect our views and opinions.

ERRORS AND OMISSIONS DISCLAIMER

While we have made every attempt to ensure that the information contained in this site has been obtained from reliable sources, STM Journals is not responsible for any errors or omissions or the results obtained from the use of this information. All information on this site is provided “as is”, with no guarantee of completeness, accuracy, timeliness, or of the results obtained from the use of this information, and without warranty of any kind, express or implied, including, but not limited to warranties of performance, merchantability, and fitness for a particular purpose.

In no event will STM Journals, its related partnerships or corporations, or the partners, agents, or employees thereof be liable to you or anyone else for any decision made or action taken in reliance on the information in this Site or for any consequential, special or similar damages, even if advised of the possibility of such damages.

GUEST CONTRIBUTORS DISCLAIMER

This Site may include content from guest contributors and any views or opinions expressed in such posts are personal and do not represent those of STM Journals or any of its staff or affiliates unless explicitly stated.

LOGOS AND TRADEMARKS DISCLAIMER

All logos and trademarks of third parties referenced on https://journals.stmjournals.com/ are the trademarks and logos of their respective owners. Any inclusion of such trademarks or logos does not imply or constitute any approval, endorsement, or sponsorship of STM Journals by such owners.

Use of AI Tools in Blog Content

Some of the blog posts published on this website are created with the assistance of Artificial Intelligence (AI) tools. While efforts are made to review and edit the content for accuracy and appropriateness, there may still be instances where unintended, unnecessary, or unverified information or claims appear.Readers are advised to use their discretion while interpreting the content. The primary purpose of using AI-generated content is to provide our audience with the most recent, diverse, and wide-ranging information on various topics. The content is intended to inform and engage, not to mislead.All external links included in the blogs are intended to guide users to real and authentic workshops, programs, or resources. The information presented through those links is curated and verified to the best of our knowledge.This disclaimer is meant to inform visitors about the use of AI in content creation, acknowledge potential limitations in content accuracy, and encourage informed and responsible reading.

CONTACT US

Should you have any feedback, comments, requests for technical support, or other inquiries, please contact us by email: [email protected].